LTX-315 triggers anticancer immunity by inducing MyD88-dependent maturation of dendritic cells.

Li XQ, Yamazaki T, He T, Alam MM, Liu J, Trivett AL, Sveinbjørnsson B, Rekdal Ø, Galluzzi L, Oppenheim JJ, Yang

Frontiers in immunology13 Mar 2024Cited by 10 (Europe PMC)

PMID38545099PMCIDPMC10967226DOI10.3389/fimmu.2024.1332922PepBankPUB-38545099

Summary

LTX-315 is a synthetic cationic oncolytic peptide with potent anticancer activity but limited toxicity for non-malignant cells. LTX-315 induces both immunogenic tumor cell death and generation of tumor-specific immune responses in multiple experimental tumor models. Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity. We found that LTX-315 treatment induces the maturation of DCs, both indirectly through the release of cancer cell-derived damage-associated molecular patterns (DAMPs)/alarmins and nucleic acids (DNA and RNA) capable of triggering distinct Toll-like receptor (TLR) signaling, and, directly by activating TLR7. The latter results in the ignition of multiple intracellular signaling pathways that promotes DC maturation, including NF-κB, mitogen activated protein kinases (MAPKs), and inflammasome signaling, as well as increased type 1 interferon production. Critically, the effects of LTX-315 on DCs the consequent promotion of anti-melanoma immunity depend on the cytosolic signal transducer myeloid differentiation response gene 88 (MyD88). These results cast light on the mechanisms by which LTX-315 induces DC maturation and hence elicits anticancer immunity, with important implications for the use of LTX-315 as an anticancer immunotherapeutic.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalOther designMechanism
In melanoma experiments, LTX‑315 promotion of antitumor immunity depended on MyD88.
In plain wordsIn preclinical melanoma experiments, LTX‑315 promotion of antitumor immunity required MyD88 signaling.
Peptide
LTX-315
Outcome
Not applicableMyD88 dependence of antitumor immunity
Study
n: not reported in source
Melanoma
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Critically, the effects of LTX-315 on DCs the consequent promotion of anti-melanoma immunity depend on the cytosolic signal transducer myeloid differentiation response gene 88 (MyD88).
1 context sentence(design, population, supporting numbers)
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509908
02LabIn vitro (cells)Mechanism
In dendritic cells, LTX‑315 induced maturation indirectly through cancer-cell DAMPs and nucleic acids and directly through TLR7 activation.
In plain wordsIn cells, LTX‑315 stimulated dendritic cell maturation through direct and indirect pathways.
Peptide
LTX-315
Outcome
IncreaseDendritic cell maturation
Study
n: not reported in source
Dendritic cells
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
We found that LTX-315 treatment induces the maturation of DCs, both indirectly through the release of cancer cell-derived damage-associated molecular patterns (DAMPs)/alarmins and nucleic acids (DNA and RNA) capable of triggering distinct Toll-like receptor (TLR) signaling, and, directly by activating TLR7.
1 context sentence(design, population, supporting numbers)
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509901
03LabIn vitro (cells)Mechanism
In dendritic cells, LTX‑315 directly activated TLR7.
In plain wordsIn cells, LTX‑315 directly activated the TLR7 immune receptor.
Peptide
LTX-315
Outcome
IncreaseTLR7 activation
Study
n: not reported in source
Dendritic cells
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
and, directly by activating TLR7.
1 context sentence(design, population, supporting numbers)
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509902
04LabIn vitro (cells)Mechanism
In dendritic cells, LTX‑315 activation of TLR7 triggered NF-kappaB signaling that promotes maturation.
In plain wordsIn cells, LTX‑315 triggered NF-kappaB signaling associated with immune cell maturation.
Peptide
LTX-315
Outcome
IncreaseNF-kappaB signaling
Study
n: not reported in source
Dendritic cells
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
The latter results in the ignition of multiple intracellular signaling pathways that promotes DC maturation, including NF-κB, mitogen activated protein kinases (MAPKs), and inflammasome signaling, as well as increased type 1 interferon production.
2 context sentences(design, population, supporting numbers)
Summary · context
and, directly by activating TLR7.
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509903
05LabIn vitro (cells)Mechanism
In dendritic cells, LTX‑315 activation of TLR7 triggered MAPK signaling that promotes maturation.
In plain wordsIn cells, LTX‑315 triggered MAPK signaling associated with immune cell maturation.
Peptide
LTX-315
Outcome
IncreaseMAPK signaling
Study
n: not reported in source
Dendritic cells
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
The latter results in the ignition of multiple intracellular signaling pathways that promotes DC maturation, including NF-κB, mitogen activated protein kinases (MAPKs), and inflammasome signaling, as well as increased type 1 interferon production.
2 context sentences(design, population, supporting numbers)
Summary · context
and, directly by activating TLR7.
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509904
06LabIn vitro (cells)Mechanism
In dendritic cells, LTX‑315 activation of TLR7 triggered inflammasome signaling that promotes maturation.
In plain wordsIn cells, LTX‑315 triggered inflammasome signaling associated with immune cell maturation.
Peptide
LTX-315
Outcome
IncreaseInflammasome signaling
Study
n: not reported in source
Dendritic cells
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
The latter results in the ignition of multiple intracellular signaling pathways that promotes DC maturation, including NF-κB, mitogen activated protein kinases (MAPKs), and inflammasome signaling, as well as increased type 1 interferon production.
2 context sentences(design, population, supporting numbers)
Summary · context
and, directly by activating TLR7.
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509905
07LabIn vitro (cells)Mechanism
In dendritic cells, LTX‑315 activation of TLR7 increased type 1 interferon production.
In plain wordsIn cells, LTX‑315 increased type 1 interferon production.
Peptide
LTX-315
Outcome
IncreaseType 1 interferon production
Study
n: not reported in source
Dendritic cells
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
The latter results in the ignition of multiple intracellular signaling pathways that promotes DC maturation, including NF-κB, mitogen activated protein kinases (MAPKs), and inflammasome signaling, as well as increased type 1 interferon production.
2 context sentences(design, population, supporting numbers)
Summary · context
and, directly by activating TLR7.
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509906
08LabIn vitro (cells)Mechanism
In dendritic cells, the effects of LTX‑315 depended on MyD88.
In plain wordsIn cells, LTX‑315 effects on dendritic cells required MyD88 signaling.
Peptide
LTX-315
Outcome
Not applicableMyD88 dependence of dendritic cell effects
Study
n: not reported in source
Dendritic cells
Outcome group
Immune response · Cancer
Studied dose
Dose not stated
Source sentences
Summary
Critically, the effects of LTX-315 on DCs the consequent promotion of anti-melanoma immunity depend on the cytosolic signal transducer myeloid differentiation response gene 88 (MyD88).
1 context sentence(design, population, supporting numbers)
Summary · context
Given the central role of dendritic cell (DC) maturation in the induction of antigen-specific immunity, we investigated the effect of LTX-315 treatment on the maturation of tumor-infiltrating DCs (TiDCs) and the generation of anti-melanoma immunity.
Show in the study text Report a problemFND-3854509907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.